425 related articles for article (PubMed ID: 36372069)
1. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
[TBL] [Abstract][Full Text] [Related]
2. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Peikert A; Martinez FA; Vaduganathan M; Claggett BL; Kulac IJ; Desai AS; Jhund PS; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Shah SJ; Katova T; Merkely B; Vardeny O; Wilderäng U; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circ Heart Fail; 2022 Oct; 15(10):e010080. PubMed ID: 36029467
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
[TBL] [Abstract][Full Text] [Related]
6. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Hegde SM; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JAMA Cardiol; 2022 Dec; 7(12):1259-1263. PubMed ID: 36190011
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
Ostrominski JW; Vaduganathan M; Selvaraj S; Claggett BL; Miao ZM; Desai AS; Jhund PS; Kosiborod MN; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Circulation; 2023 Dec; 148(24):1945-1957. PubMed ID: 37830208
[TBL] [Abstract][Full Text] [Related]
8. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
[TBL] [Abstract][Full Text] [Related]
9. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Tamborlane WV; Laffel LM; Shehadeh N; Isganaitis E; Van Name M; Ratnayake J; Karlsson C; Norjavaara E
Lancet Diabetes Endocrinol; 2022 May; 10(5):341-350. PubMed ID: 35378069
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.
Jhund PS; Claggett BL; Talebi A; Butt JH; Gasparyan SB; Wei LJ; McCaw ZR; Wilderäng U; Bengtsson O; Desai AS; Petersson M; Langkilde AM; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Vaduganathan M; Solomon SD; McMurray JJV
JAMA Cardiol; 2023 Jun; 8(6):554-563. PubMed ID: 37099283
[TBL] [Abstract][Full Text] [Related]
14. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668
[TBL] [Abstract][Full Text] [Related]
15. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
18. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.
Peikert A; Goyal P; Vaduganathan M; Claggett BL; Kulac IJ; Miao ZM; Vardeny O; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2023 Oct; 11(10):1380-1393. PubMed ID: 37294244
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
